Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20798258 | 0.78 | APLNR (0.37) | KMT2AALDH1A1 | |
| SCHEMBL11518296 | 0.78 | APLNR (0.37) | KMT2AALDH1A1 | |
| SCHEMBL9287951 | 0.78 | KMT2A (0.34) | KMT2AALDH1A1 | |
| SCHEMBL4194994 | 0.74 | — | — | |
| SCHEMBL9281093 | 0.74 | KMT2A (0.32) | KMT2A | |
| SCHEMBL30839529 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2GAA | |
| SCHEMBL31629840 | 0.73 | KMT2A (0.32) | SMN1; SMN2KMT2APKM | |
| SCHEMBL21603676 | 0.73 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL18732366 | 0.70 | EPHX1 (0.31) | KMT2AALDH1A1 | |
| SCHEMBL938236 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867225-B1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2017-08-09 | — | — | EP | claimed |
| US-9468661-B2 | Pyrrolidine derivatives and their use as complement pathway modulators | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | claimed |
| CN-104619698-B | Pyrrolidin derivatives and the purposes as complement pathway regulator thereof | 诺华股份有限公司 | 2016-08-31 | — | — | CN | claimed |
| US-20150190457-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2015-07-09 | — | — | US | claimed |
| EP-2867225-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | Novartis AG (CH) | 2015-05-06 | — | — | EP | claimed |
| WO-2014002054-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | claimed |
| EP-2867225-B1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2017-08-09 | — | — | EP | disclosed |
| US-9468661-B2 | Pyrrolidine derivatives and their use as complement pathway modulators | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| CN-104619698-B | Pyrrolidin derivatives and the purposes as complement pathway regulator thereof | 诺华股份有限公司 | 2016-08-31 | — | — | CN | disclosed |
| US-20150190457-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2015-07-09 | — | — | US | disclosed |
| EP-2867225-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014002054-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| US-5147868-A | For selectively inhibiting the metabolism of dipeptidase; useful in mixtures with bactericides | MERCK & CO., INC. (US) | 1992-09-15 | — | — | US | disclosed |
| EP-0161546-A1 | Combination of 2-substituted carbapenems with dipeptidase inhibitors | MERCK & CO. INC. (US) | 1985-11-21 | — | — | EP | disclosed |
| US-4539208-A | Combination of thienamycin-type antibiotics with dipeptidase inhibitors | MERCK & CO., INC. (US) | 1985-09-03 | — | — | US | disclosed |
| EP-0010573-B1 | NOVEL Z-2-ACYLAMINO-3-MONOSUBSTITUTED PROPENIC ACIDS AND THEIR ESTERS AND SALTS, AND PROCESSES FOR PREPARING THEM | MERCK & CO. INC. (US) | 1983-10-19 | — | — | EP | disclosed |
| EP-0072014-A1 | Combination of 2-substituted penems with dipeptidase inhibitors | MERCK & CO. INC. (US) | 1983-02-16 | — | — | EP | disclosed |
| EP-0007614-B1 | AN ANTIBACTERIAL COMPOSITION OF THIENAMYCIN-TYPE COMPOUND AND A DIPEPTIDASE INHIBITOR | MERCK & CO. INC. (US) | 1983-01-26 | — | — | EP | disclosed |
| EP-0010573-A1 | Novel Z-2-acylamino-3-monosubstituted propenic acids and their esters and salts, and processes for preparing them | MERCK & CO. INC. (US) | 1980-05-14 | — | — | EP | disclosed |
| EP-0007614-A1 | An antibacterial composition of thienamycin-type compound and a dipeptidase inhibitor | MERCK & CO. INC. (US) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150190457-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | C5, C9, TFPI | SMN1; SMN2 4539/4885GAA 3510/4885KMT2A 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.